Key highlights
7* tests contributing to saving costs and protecting life
USD 1.8bn serviceable market with 5-10% annual growth
Entered partnerships with 5 major global IVD companies
Scalable, lean and flexible commercial model
Delivered ~30% annual revenue growth 2019-23
2 ‘blockbuster’ tests in market and product development
Industry leading team and knowhow
Team with proven track-record and industry expertise from market leading IVD companies
Gentian’s strategy for long-term growth and value creation
Gentian Diagnostic’s purpose is to deliver efficient diagnostics for better treatment decisions.
The growing diagnostics market puts increasing pressure on clinical laboratory efficiency. However, many of the existing, clinically relevant biomarkers are available only on slow and inefficient platforms. Gentian’s solution is to utilise PETIA (Particle-Enhanced Turbidimetric Immunoassays), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers.
Gentian’s portfolio of high-impact diagnostic tests targets several large and growing disease areas such as infections and inflammation, kidney failure and congestive heart failure. The company has four established products – Cystatin C, fCAL® turbo, Canine CRP and fPELA® turbo – that contributed to 30% annual revenue growth in 2019-2023. The most recent launch in Q3 2023 of Retinol-Binding Protein (RBP) will support growth for this category. In addition, GCAL® has been launched and is in market development while NT-proBNP is in the product development phase – with the two latter having potential to become growth accelerators. The company also has undisclosed projects in exploration and ‘proof of concept’ phases.
The company’s roadmap for long-term growth and value creation is founded on six strategic pillars:
- Grow annual revenue from the company’s established products by 20%+ annually – by expanding market access through additional commercial partners and regulatory approvals.
- Demonstrate clinical relevance of GCAL® for the early detection of severe infections.
- Bring a steady stream of new high-impact diagnostic tests to market.
- Secure one new contract with a global commercial partner every year, building on already established partnerships with major diagnostic companies across products.
- Grow gross margin from ~50% to 60%+ through economies of scale.
- Deliver long-term EBITDA margins of 40% through operational leverage and cost discipline.
*5 established tests, 1 in market development and further 1 in product development.
Gentian Diagnostics ASA - Prospectus
